

Repatha (evolocumab, anti-PCSK9 antibody) related patents in Japan ((1)-(6))

■(1) Japanese patent No. 5441905 (CDR)

■Patent owner: Amgen

[Claim 1] An isolated **neutralizing monoclonal antibody** that binds to a **PCSK9 protein**, wherein the neutralizing monoclonal antibody comprises a heavy chain polypeptide comprising a heavy chain **CDR1** that is a CDR1 of SEQ ID NO: 368, a heavy chain CDR2 that is a CDR2 of SEQ ID NO: 175, and a heavy chain CDR3 that is a CDR3 of SEQ ID NO: 180, and a light chain polypeptide comprising a light chain CDR1 that is a CDR1 of SEQ ID NO: 158, a light chain CDR2 that is a CDR2 of SEQ ID NO: 162, and a light chain CDR3 that is a CDR3 of SEQ ID NO: 395.